Go to content
Attention:

Lukt het niet om in te loggen op het AFM Portaal?

Het kan helpen om uw browsergeschiedenis/cookies te verwijderen

Crucell N.V.

Crucell N.V.

Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.

Publicatie datum 17 aug 2009 - 08:20
Statutaire naam Crucell N.V.
Titel ew awards of $300 million for Quinvaxem® bringing total value up to $800 million
Bericht Leiden, The Netherlands (17 August, 2009) – Dutch biopharma company Crucell N.V. (Euronext, Nasdaq: CRXL; Swiss Exchange: CRX) today announced that a large supranational organization has awarded the first portion of new contracts worth $300 million for supplies of Crucell’s Quinvaxem® paediatric vaccine. The new contracts are the largest ever received by Crucell and cover the period 2010–2012, with the initial awarded amount expected to grow even further over those three years. These contracts are in addition to the $500 million obtained over the tender period 2007–2009, and support the superior quality and reliability of Crucell’s fully-liquid pentavalent vaccine. They bring the total value of contracts awarded since the launch of Quinvaxem® at the end of 2006 to $800 million. During the first tender round in 2006, Crucell was initially awarded $230 million (Dec 2006) and received additional incremental awards of $130 million and $140 million in May and September, 2008, respectively.